Tag:

Robert McNally

Latest Headlines

Latest Headlines

GeoVax: Meeting the HIV vaccine challenge

June 14, 2012 | By
"The development of HIV vaccines has been slow, because the research community had to determine what genetic material would trigger both an antibody and a T cell response. Many times you need to find out what doesn't work first, but the research is now speeding up," says Robert McNally, Ph.D., president and CEO of GeoVax, in an interview with FierceVaccines.
Related Tags
Press Releases
  • Philips Volcano announces more than 5,000 Coronary Artery Disease patients enrolled in iFR Outcomes Trials
  • Sun Pharma enters Japanese prescription market
  • Veracyte Secures Up to $45 Million in Financing from Visium Healthcare Partners
  • Merck Statement on hep C verdict
  • Quanterix Raises $46 Million in Series D Financing
  • More Press Releases
Sponsored Links